Encompass Health Corp Files 8-K
Ticker: EHC · Form: 8-K · Filed: Dec 1, 2025 · CIK: 785161
Sentiment: neutral
Topics: regulation-fd, disclosure
TL;DR
Encompass Health filed an 8-K on Dec 1, 2025, for Reg FD disclosure.
AI Summary
Encompass Health Corporation filed an 8-K on December 1, 2025, to report information under Regulation FD. The filing does not detail specific transactions or events but serves as a notification of information disclosure.
Why It Matters
This filing indicates Encompass Health Corporation is making a disclosure under Regulation FD, which ensures fair and timely dissemination of material information to investors.
Risk Assessment
Risk Level: low — The filing is a standard regulatory disclosure and does not contain information about significant financial events or operational changes.
Key Players & Entities
- Encompass Health Corporation (company) — Registrant
- December 1, 2025 (date) — Date of earliest event reported
- Regulation FD (regulation) — Disclosure requirement
FAQ
What is the purpose of this Form 8-K filing?
The Form 8-K is filed to report information under Regulation FD, ensuring fair disclosure of material information.
When was the earliest event reported in this filing?
The earliest event reported is dated December 1, 2025.
What is the company's principal executive office address?
The address is 9001 Liberty Parkway, Birmingham, Alabama 35242.
What is Encompass Health Corporation's IRS Employer Identification Number?
The IRS Employer Identification Number is 63-0860407.
Under which section of the Securities Exchange Act is this report filed?
This report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 1,543 words · 6 min read · ~5 pages · Grade level 20 · Accepted 2025-12-01 16:28:25
Key Financial Figures
- $0.01 — ich registered Common Stock, par value $0.01 per share EHC New York Stock Exchange
- $5,905 million — 2025 ranges: Net operating revenue of $5,905 million to $5,955 million; Adjusted EBITDA of
- $5,955 million — operating revenue of $5,905 million to $5,955 million; Adjusted EBITDA of $1,235 million to
- $1,235 million — to $5,955 million; Adjusted EBITDA of $1,235 million to $1,255 million; and Adjusted earnin
- $1,255 million — ; Adjusted EBITDA of $1,235 million to $1,255 million; and Adjusted earnings per share from
- $5.22 — ons attributable to Encompass Health of $5.22 to $5.37. The information contained he
- $5.37 — butable to Encompass Health of $5.22 to $5.37. The information contained herein is b
- $125 million — debt discounts and fees - approximately $125 million Amortization of debt-related items - a
- $10 million — n of debt-related items - approximately $10 million Forward-Looking Statements Statement
Filing Documents
- ehc-20251201.htm (8-K) — 32KB
- 0000785161-25-000118.txt ( ) — 148KB
- ehc-20251201.xsd (EX-101.SCH) — 2KB
- ehc-20251201_lab.xml (EX-101.LAB) — 21KB
- ehc-20251201_pre.xml (EX-101.PRE) — 12KB
- ehc-20251201_htm.xml (XML) — 3KB
01. Regulation FD Disclosure
ITEM 7.01. Regulation FD Disclosure. Members of Encompass Health Corporation's (the "Company" or "Encompass Health") senior management team are scheduled to meet with investors and analysts at various meetings on December 2, 2025 and December 3, 2025. The Company reiterates as of the date hereof its guidance previously reported in the Current Report on Form 8-K, dated October 29, 2025, and during the Company's earnings conference call held on October 30, 2025. Accordingly, the Company continues to expect the following full-year 2025 ranges: Net operating revenue of $5,905 million to $5,955 million; Adjusted EBITDA of $1,235 million to $1,255 million; and Adjusted earnings per share from continuing operations attributable to Encompass Health of $5.22 to $5.37. The information contained herein is being furnished pursuant to Item 7.01 of Form 8-K, "Regulation FD Disclosure." This information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. The furnishing of this information will not be deemed an admission as to the materiality of any information contained herein. Note Regarding Presentation of Non-GAAP Financial Measures Excluding net operating revenues, the Company does not provide guidance on a GAAP basis because it is unable to predict, with reasonable certainty, the future impact of items that are deemed to be outside the control of the Company or otherwise not indicative of its ongoing operating performance. Such items include government, class action, and related settlements; professional fees—accounting, tax, and legal; mark-to-market adjustments for stock appreciation rights; gains or losses related to hedging instruments; loss on early extinguishment of debt; adjustments to its income tax
Forward-Looking Statements
Forward-Looking Statements
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized. ENCOMPASS HEALTH CORPORATION By: / S / D OUGLAS E. C OLTHARP Name: Douglas E. Coltharp Title: Executive Vice President and Chief Financial Officer Dated: December 1, 2025